CO2017010573A2 - Un análogo de trifluoroetil quinolina específico para uso en el tratamiento del síndrome de sjögren - Google Patents
Un análogo de trifluoroetil quinolina específico para uso en el tratamiento del síndrome de sjögrenInfo
- Publication number
- CO2017010573A2 CO2017010573A2 CONC2017/0010573A CO2017010573A CO2017010573A2 CO 2017010573 A2 CO2017010573 A2 CO 2017010573A2 CO 2017010573 A CO2017010573 A CO 2017010573A CO 2017010573 A2 CO2017010573 A2 CO 2017010573A2
- Authority
- CO
- Colombia
- Prior art keywords
- sjögren
- trifluoroethyl
- syndrome
- treatment
- analogue specific
- Prior art date
Links
- 208000021386 Sjogren Syndrome Diseases 0.000 title abstract 2
- JOAPFEPXYNWUKS-UHFFFAOYSA-N 2-(2,2,2-trifluoroethyl)quinoline Chemical class C1=CC=CC2=NC(CC(F)(F)F)=CC=C21 JOAPFEPXYNWUKS-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 abstract 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 abstract 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506786.1A GB201506786D0 (en) | 2015-04-21 | 2015-04-21 | Therapeutic use |
| PCT/EP2016/058810 WO2016170014A1 (en) | 2015-04-21 | 2016-04-20 | A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017010573A2 true CO2017010573A2 (es) | 2018-03-09 |
Family
ID=53298950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0010573A CO2017010573A2 (es) | 2015-04-21 | 2017-10-17 | Un análogo de trifluoroetil quinolina específico para uso en el tratamiento del síndrome de sjögren |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10493074B2 (OSRAM) |
| EP (1) | EP3285772B1 (OSRAM) |
| JP (1) | JP6721606B2 (OSRAM) |
| KR (1) | KR102627370B1 (OSRAM) |
| CN (1) | CN107530344B (OSRAM) |
| AR (1) | AR105552A1 (OSRAM) |
| AU (1) | AU2016251236B2 (OSRAM) |
| BR (1) | BR112017020591B8 (OSRAM) |
| CA (1) | CA2981631C (OSRAM) |
| CL (1) | CL2017002669A1 (OSRAM) |
| CO (1) | CO2017010573A2 (OSRAM) |
| CY (1) | CY1122572T1 (OSRAM) |
| DK (1) | DK3285772T3 (OSRAM) |
| EA (1) | EA032432B1 (OSRAM) |
| ES (1) | ES2763335T3 (OSRAM) |
| GB (1) | GB201506786D0 (OSRAM) |
| HR (1) | HRP20192273T1 (OSRAM) |
| HU (1) | HUE047162T2 (OSRAM) |
| IL (1) | IL254766B (OSRAM) |
| LT (1) | LT3285772T (OSRAM) |
| MX (1) | MX2017013148A (OSRAM) |
| MY (1) | MY192972A (OSRAM) |
| PL (1) | PL3285772T3 (OSRAM) |
| PT (1) | PT3285772T (OSRAM) |
| SG (1) | SG11201707789YA (OSRAM) |
| SI (1) | SI3285772T1 (OSRAM) |
| WO (1) | WO2016170014A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2873875T3 (es) * | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| DK2137186T3 (en) * | 2007-03-23 | 2016-04-18 | Amgen Inc | Heterocyclic compounds and their uses |
| PT2496567T (pt) * | 2009-11-05 | 2017-11-15 | Rhizen Pharmaceuticals S A | Novos moduladores de quinase benzopiran |
| UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| JP6030783B2 (ja) * | 2013-06-14 | 2016-11-24 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
-
2015
- 2015-04-21 GB GBGB1506786.1A patent/GB201506786D0/en not_active Ceased
-
2016
- 2016-04-20 EA EA201792318A patent/EA032432B1/ru not_active IP Right Cessation
- 2016-04-20 MY MYPI2017703917A patent/MY192972A/en unknown
- 2016-04-20 PL PL16719356T patent/PL3285772T3/pl unknown
- 2016-04-20 SI SI201630565T patent/SI3285772T1/sl unknown
- 2016-04-20 WO PCT/EP2016/058810 patent/WO2016170014A1/en not_active Ceased
- 2016-04-20 PT PT167193564T patent/PT3285772T/pt unknown
- 2016-04-20 CA CA2981631A patent/CA2981631C/en active Active
- 2016-04-20 MX MX2017013148A patent/MX2017013148A/es active IP Right Grant
- 2016-04-20 ES ES16719356T patent/ES2763335T3/es active Active
- 2016-04-20 AR ARP160101079A patent/AR105552A1/es not_active Application Discontinuation
- 2016-04-20 DK DK16719356.4T patent/DK3285772T3/da active
- 2016-04-20 LT LTEP16719356.4T patent/LT3285772T/lt unknown
- 2016-04-20 SG SG11201707789YA patent/SG11201707789YA/en unknown
- 2016-04-20 EP EP16719356.4A patent/EP3285772B1/en active Active
- 2016-04-20 HR HRP20192273TT patent/HRP20192273T1/hr unknown
- 2016-04-20 BR BR112017020591A patent/BR112017020591B8/pt active IP Right Grant
- 2016-04-20 HU HUE16719356A patent/HUE047162T2/hu unknown
- 2016-04-20 KR KR1020177031275A patent/KR102627370B1/ko active Active
- 2016-04-20 JP JP2017554426A patent/JP6721606B2/ja active Active
- 2016-04-20 CN CN201680022982.1A patent/CN107530344B/zh active Active
- 2016-04-20 US US15/565,866 patent/US10493074B2/en active Active
- 2016-04-20 AU AU2016251236A patent/AU2016251236B2/en not_active Ceased
-
2017
- 2017-09-28 IL IL254766A patent/IL254766B/en active IP Right Grant
- 2017-10-17 CO CONC2017/0010573A patent/CO2017010573A2/es unknown
- 2017-10-20 CL CL2017002669A patent/CL2017002669A1/es unknown
-
2019
- 2019-12-23 CY CY20191101354T patent/CY1122572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| CO2018013559A2 (es) | Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds) | |
| HUE053704T2 (hu) | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| HUE037558T2 (hu) | Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében | |
| CL2015000784A1 (es) | Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2018001171A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| MX2022002954A (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. | |
| MX2020004411A (es) | Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren. | |
| DK3463436T3 (da) | Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| CO2017010573A2 (es) | Un análogo de trifluoroetil quinolina específico para uso en el tratamiento del síndrome de sjögren | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| WO2017095918A3 (en) | Methods for treating cancer using rspo3 antagonists | |
| WO2016073652A8 (en) | Iminosugars useful for the treatment of viral diseases | |
| IT201700109607A1 (it) | Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma. | |
| CL2018001871A1 (es) | Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario | |
| AR115575A1 (es) | Antagonista gremlin-1 para la prevención y tratamiento del cáncer | |
| UA115417U (xx) | Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі | |
| IT201700056680A1 (it) | Composizione per l’uso nella prevenzione e nel trattamento della disfunzione erettile. | |
| CL2015003683A1 (es) | Letermovir amorfo formulación oral farmacéutica que lo comprende uso de la formulación en la preparación de un medicamento útil en el tratamiento yo profilaxis de enfermedades asociadas con el grupo de herpesviridae, preferiblemente asociadas con citomegalovirus cmv proceso de preparación de letermovir amorfo. |